| 1 |
34954768 | Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy. | 2022 Jun 1 |
1 |
| 2 |
35177224 | Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia? | 2022 Feb |
1 |
| 3 |
33093222 | F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA. | 2021 Jan 5 |
1 |
| 4 |
34209594 | The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began with the Placenta. | 2021 Jun 29 |
1 |
| 5 |
28844979 | Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation. | 2017 Nov |
1 |
| 6 |
25286881 | Novel antiplatelet agents in acute coronary syndrome. | 2015 Jan |
1 |
| 7 |
25600441 | Normal platelet activation profile in patients with peripheral arterial disease on aspirin. | 2015 Mar |
1 |
| 8 |
25700561 | Current antiplatelet agents: place in therapy and role of genetic testing. | 2015 Apr |
1 |
| 9 |
24268424 | Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. | 2014 Jan |
1 |
| 10 |
23313628 | Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition. | 2013 May |
1 |
| 11 |
22393298 | Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. | 2012 |
1 |
| 12 |
22932716 | Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. | 2012 Oct 13 |
1 |
| 13 |
21819272 | Vorapaxar: a novel protease-activated receptor-1 inhibitor. | 2011 Oct |
1 |
| 14 |
19890703 | Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement. | 2009 Dec |
1 |
| 15 |
15381054 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. | 2004 Sep 24 |
1 |